Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1403 • ACR Convergence 2025
Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
Anna Kuhn¹, Magdalena Seng², Björn Christian Frye³, Sebastian Fähndrich³, Lydia Vollmer³, Jacques-eric GOTTENBERG⁴, Florian Kollert⁵, Reinhard Voll⁶ and Stephanie Finzel⁷, ¹¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, Freiburg, Germany, ²¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; ²University Medical Center, Department of Radiology and Nuclear medicine, Basel, Switzerland, Freiburg, Germany, ³³University Medical Center, Department of Pulmonology, Freiburg, Germany, Freiburg, Germany, ⁴Hautepierre Hospital, STRASBOURG, Alsace, France, ⁵¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern; Switzerland Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶University Medical Center Freiburg, Freiburg, Germany, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Background/Purpose: About 70% of patients with primary Sjögren's disease (pSjD) suffer from fatigue. Fatigue is associated with functional deficits(1), leading to anxiety, depression and reduced…
Abstract Number: 1386 • ACR Convergence 2025
Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
Hoang Nguyen¹, Philip Moresco², Antoine Chiu², Asha Patnaik³ and Peter Gorevic⁴, ¹Stony Brook University-Renaissance School of Medicine- Department of Rheumatology, Jamaica, NY, ²Stony Brook University -Renaissance School of Medicine, Stony Brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Stony Brook University, Stony Brook, NY
Background/Purpose: -Sjogren’s syndrome (SS) is a chronic autoimmune disorder, defined by keratoconjunctivitis sicca (KCS), specific serologies, and a significant risk of extra-exocrine disease manifestations and…
Abstract Number: 0899 • ACR Convergence 2025
Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease
Caroline Atlas¹, Balakrishnan Kamaraj¹, Omid Jamshidi¹, Adam Mor¹, Yevgeniya Gartshteyn², Teja Kapoor³ and Robert Winchester¹, ¹Columbia University, New York, NY, ²Columbia University Medical Center, Glen Rock, NJ, ³Columbia University Irving Medical Center, New York, NY
Background/Purpose: Sicca symptoms may develop in the setting of immune checkpoint inhibitor (ICI) therapy and are clinically indistinguishable from those encountered in Sjogren’s disease (SjD).…
Abstract Number: 0506 • ACR Convergence 2025
Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
Songyuan Yao¹, Christina Lawrence¹, Hope Christakos², Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Tommi C. Taylor¹, Astrid Rasmussen¹, Kiely Grundahl², R Hal Scofield¹, Blake M. Warner³, Judith James¹, Joel Guthridge¹, Christopher J. Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Clinical tests for Sjögren’s disease (SjD) often overlook Ro-seronegative (RoNeg) cases, leading to delayed or missed diagnoses. Identifying additional serum autoantibodies could improve diagnostic…
Abstract Number: 2301 • ACR Convergence 2025
Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Sara M. Stern¹, Angela Merritt², Ludovic Trinquart³, Emma Barnboym⁴, Michelle LeeBravatti³, Suzy Richins⁵, Tressie L. Rollins⁵, Hanna M. Salzman⁵, Marisha Palm³, Cortney M. Wieber⁶, Hermine Brunner⁷ and Nora G. Singer⁸, ¹University of Utah, Salt Lake City, UT, ²Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ³Tufts University School of Medicine, Boston, MA, ⁴The MetroHealth System at Case Western Reserve University School of Medcine, Cleveland, OH, ⁵Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁶Institute for Clinical Research and Health Policy Studies (ICRHPS) and CTSI, Tufts School of Medicine, Boston, MA, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Childhood Sjogren Disease (cSjD) is a rare disease that presents with a wide variety of symptoms. Compared to adult SjD, cSjD more frequently manifests…
Abstract Number: 2017 • ACR Convergence 2025
Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
Ivana Ilic, Anchal Sabharwal, Galina Marder and Sonali Narain, Northwell, Great Neck
Background/Purpose: Interstitial lung disease is a major cause of morbidity and mortality in patients with connective tissue disease (CTD-ILD). Evaluation of ILD severity and progression…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…
Abstract Number: 1385 • ACR Convergence 2025
Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome
Giovanni Fulvio¹, Rossana Izzetti², Francesco Gulia², Valentina Donati³, Gaetano La Rocca⁴, Inmaculada Concepción Navarro García⁵, Beatrice Dei¹, Francesco Ferro⁶, Marta Mosca⁷ and Chiara Baldini⁷, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Unit of Dentistry and Oral Surgery, Pisa, Italy, ³Azienda Ospedaliero-Universitaria Pisana (AOUP), Unit of Pathological Anatomy ², Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁵University of Pisa, Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁶Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Ocular and oral dryness, occurring in isolation, represent distinct phenotypic subsets within Sjögren’s disease (SjD). However, potential differences in glandular imaging findings and pathophysiological…
Abstract Number: 0521 • ACR Convergence 2025
Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression
Yukitomo Hagiwara¹, Goh Murayama², Taiga Kuga³, Yujin Nishioka⁴, Masaki Nojima¹, Takumi Saito⁵, Yu Yamaji⁶, Tomoko Miyashita⁶, Makio Kusaoi⁷, Ken Yamaji⁵ and Naoto Tamura⁸, ¹Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ³Juntendo University, Tokyo, Japan, ⁴Juntendo University, Department of Internal Medicine and Rheumatology, Shizuoka, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, ⁷Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo, Tokyo, Japan, ⁸Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren's disease (pSD) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
Abstract Number: 0046 • ACR Convergence 2025
Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
Thomas Riley¹, Dana DiRenzo¹, Ellen Romich², Michael Levin³, Scott Damrauer³, Michael George¹, Montserrat Anguera¹, Joshua Baker¹ and Nikhil Jiwrajka¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female…
Abstract Number: 2300 • ACR Convergence 2025
Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
sandrine jousse¹, Valerie Devauchelle², baptiste quere¹, Divi Cornec³, Caroline Denis⁴, Thierry MARHADOUR¹, Alice Tison¹, Patricia Baley⁴, Alain SARAUX⁵, Noemi Giglioli⁶, CAROLE SIPS⁶, Shuqi Chen⁷, Rainer Hillenbrand⁶, Richard Siegel⁸, Wolfgang Hueber⁹, Claire Bonal⁶ and Didier Laurent⁶, ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²UBO, Brest, France, ³LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁴CHU Brest, Brest, France, Brest, France, ⁵CHU Brest, Brest, France, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷China Novartis Institutes for BioMedical Research, Shanghai, China, Shangai, China (People's Republic), ⁸Novartis Biomedical Research, Basel, Switzerland, ⁹Novartis Pharmaceuticals, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered, fully human IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions through dual mechanism of…
Abstract Number: 1964 • ACR Convergence 2025
Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Syndrome
Otto Olivas¹, Mónica García-Sevilla², Lucía Cubero², Javier Pascau² and Esperanza Naredo³, ¹Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain, Madrid, Madrid, Spain, ²Department of Bioengineering, Carlos III University of Madrid, Leganes, Madrid, Spain and Health Research Institute Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ³Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain, MADRID, Spain
Background/Purpose: To develop a deep learning model for classifying ultrasound images of salivary glands (SG) [parotid (PG) and submandibular (SMG)] based on the Outcome Measures…
Abstract Number: 1401 • ACR Convergence 2025
Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States
Sara McCoy¹, Anjana Lalla², Nilesh Choudhary³, Shraddha Chatterjee³, Shiwani Prasad³ and Antton Egana², ¹University of Wisconsin–Madison, Madison, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis India, Hyderabad, India
Background/Purpose: SjD is a chronic, systemic, progressive autoimmune disease characterized by dry mouth and eyes, but it is often accompanied by extraglandular symptoms and signs…
Abstract Number: 1384 • ACR Convergence 2025
Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
Ghaith Noaiseh¹, Arun Varadhachary², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹University of Kansas Medical Center, Kansas City, KS, ²Washington University in St. Louis, St. Louis, MO, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is recognized as a multifaceted autoimmune disease impacting almost any organ or body system. Of particular importance is the central nervous system…
Abstract Number: 0519 • ACR Convergence 2025
A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study
Shu Liu¹, Guanhao Wu¹, Mengge Pan¹, Qi Sun², Jingchen Gao¹, Xianming Long³, Chaogui Tang⁴, Xinran Yuan¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China (People's Republic), ²Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong, China, Nantong, China (People's Republic), ³The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China (People's Republic), ⁴The Affiliated Huaian First People’s Hospital of Nanjing Medical University, Huai’an First People’s Hospital, Nanjing Medical University, Huaian, China (People's Republic)
Background/Purpose: Primary Sjögren's syndrome (pSS) is a prevalent systemic autoimmune disorder. However, the early and accurate diagnosis of pSS remains challenging due to its non-specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].